Congratulations to: 
Dr. Christopher Ong (General Surgery) who has received 0.5 million dollars from Prostate Cancer Canada to fund his clinical trials of “Therapeutic protein inhibitors of SEMA3C in treatment of advanced prostate cancer”.
Dr. Ong’s lab discovered that all epithelial cancers (including prostate, breast, bladder) require the growth factor SEMA3C to survive. Furthermore, previously described growth factor receptor pathways such as Her2, HGF, VEGF SEMA3C actually work through SEMA3C….. so SEMA3C inhibitors will work as a master drug for treatment of these cancers.
posted : 2015-January-12